NCT04245527WithdrawnNot Applicable
Joovvin' for Hormonal Health
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- ProofPilot
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Testosterone Change
Study Overview
Brief Summary
8-week pilot study looking at the impact of Joovv's infrared photo modulation product on male and female hormone levels.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •United States resident
Exclusion Criteria
- •current Joovv or other photomodulation therapy user
- •under medical supervision for medically treatable illness
- •significant travel during study period
- •use of birth control
Arms & Interventions
Study Arm
Experimental
20 minutes Joovv Solo every day for 8 weeks.
Intervention: Joovv Infrared Light Device (Device)
Outcomes
Primary Outcomes
Testosterone Change
Time Frame: baseline to week 8
in males, change from baseline to week 8
change of thyroid-stimulating hormone (TSH)
Time Frame: baseline to week 8
in females change in estrogen and progesterone from baseline to week 8
Self report general wellness
Time Frame: baseline to week 8
series of questions at baseline and week 8 on general wellness (modified Short Form-36)
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)HealthyNCT03111511Janssen Sciences Ireland UC18
Completed
Phase 1
A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and NorethindroneHealthyNCT02652650Janssen Research & Development, LLC18
Withdrawn
Phase 1
Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440HealthyNCT03890341Janssen Research & Development, LLC
Terminated
Phase 1
A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy FemalesHealthyNCT03126097Janssen Research & Development, LLC18
Completed
Phase 2
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsDyslipidemiaNCT00688558Akros Pharma Inc.92